Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049801 · ClinicalTrials.gov registry record · Phase 1
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Bruno C. Medeiros.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02049801: Clinical Trial Phase 1 study, sponsored by Bruno C. Medeiros.
NCT02049801 is a Phase 1 study that was terminated before completion, run by Bruno C. Medeiros. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02049801, a Phase 1 study, was terminated before completion, sponsored by Bruno C. Medeiros.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. MEK inhibitor MEK162 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MEK inhibitor MEK162, cytarabine, and idarubicin may be an effective treatment for acute myeloid leukemia.
Primary Outcome
Dose limiting toxicities will be tabulated by dose, severity and major organ system.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG cytarabine
- DRUG idarubicin
- DRUG MEK inhibitor MEK162
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-11-01 |
| Phase | Phase 1 |
Why NCT02049801 stopped before completion
NCT02049801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02049801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02049801 about?
NCT02049801 is a clinical study titled "MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine. MEK inhibitor MEK162 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytar...
What is the current status of trial NCT02049801?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-12. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT02049801?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), cytarabine (DRUG), idarubicin (DRUG), MEK inhibitor MEK162 (DRUG).
Who is sponsoring clinical trial NCT02049801?
This trial is sponsored by Bruno C. Medeiros, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02049801's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia